| Author, Year | Randomization Adequate? | Allocation Concealment Adequate? | Groups Similar at Baseline? | Eligibility Criteria Specified? | Outcome Assessors Masked? | Care Provider Masked? | Patient Masked? | Reporting of Attrition, Crossovers, Adherence, and Contamination? | Loss to Followup and Attrition: Differential/High? | Intention-to-Treat Analysis? | Quality Rating | Funding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chan, 2007235 | Yes | Yes | Yes | Yes | Yes | Unclear | Unclear | Yes; Unclear; Yes; Yes | Yes; No | Yes | Fair | Research grant |
| Chan, 2010295 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes; No; Yes; No | Yes; Yes | Yes | Fair | Pfizer |
| Cheung, 201082 | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes; No; No; No | No; No | Yes, >95% included in ITT | Fair | Pfizer |
| Dahlberg, 200952 | Yes | Unclear | Yes | Yes | Yes | Yes | Yes | No; No; Yes; No | No; Yes | Yes | Fair | Pfizer |
| Dequeker, 199860 | Unclear | Unclear | Yes | No | Unclear | Unclear | Yes | No; No; No; No | No; No | No | Fair | Boehringer Ingelheim |
| Dickson, 1991298 | Unclear | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes; No; No; No | No; Yes | No | Fair | Pfizer Ltd. |
| Emery, 200853 | Yes | No | No | Yes | Unclear | Yes | Yes | Yes; No; Yes; No | Yes; Yes | No | Fair | Pfizer |
| Feng, 2008116 | Unclear | Unclear | Yes | Yes | Yes | Yes | Yes | No; No; Yes; No | Unclear; Unclear | No | Fair | Chinese Government |
| Furst, 200161 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | No | Fair | Boehringer Ingelheim |
| Goldstein, 200088 | Yes | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | Yes | Fair | GD Searle; Pfizer |
| Goldstein, 2007254 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes, No, No, No | Yes, No | No | Fair | TAP pharmaceuticals |
| Goldstein, 2010253 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes; No; Yes; No | No, Yes | Yes | Fair | AstraZeneca |
| Hawkey, 199663 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | Unclear | Fair | NR |
| Herrero-Beaumont, 2007206 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes; No; Yes; No | No; Yes | Yes | Fair | Rottapharm |
| Hosie, 199664 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | Yes | Fair | NR |
| Kahan, 2009209 | Yes | Unclear | Yes | Yes | Yes for radiographs, Unclear for other outcome assessment | Yes | Yes | Yes; No; Yes; No | No; Yes (32% at 2 years) | Yes | Fair | IBSA and Genevrier Laboratories |
| Kosuwon 2010312 | Yes | Unclear | Yes | Yes | Yes | Yes | Yes | Yes; NA; Yes; No | No; No | Yes, >95% included in ITT | Fair | Faculty of Medicine, Khon Kaen University and Bangkok Drug Company |
| Linden, 199666 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | No | Fair | NR |
| Mazieres, 2007210 | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes; No; Yes; No | No; No | Yes | Fair | Pierre Fabre Company |
| McKenna, 1998284 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | Yes | Fair | NR (Pharmacia) |
| Messier, 2007213 | Unclear | Unclear | No | Yes | Unclear | Yes | Yes | Yes; No; Yes; No | No; No | Yes | Fair | Rexall Sundown |
| Michel, 2005211 | Yes | Unclear | Yes | Yes | Yes for reading radiographs, Unclear for other outcome assessment | Yes | Yes | Yes; No; Yes; No | No; Yes | Yes | Fair | NR |
| Moller, 2010212 | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Chondroitin: 9.4% Placebo: 20% | Yes; No | No | Fair | Bioiberica |
| Rother, 2007299 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes; Yes; Yes; No | No; No | Yes | Good | IDEA AG and McNeall Consumer and Specialty Pharmaceuticals |
| Rozendaal, 2008207 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes; No; Yes; No | No; No | Yes | Good | Erasmus Medical Center |
| Sandelin, 1997300 | Unclear | Unclear | Yes | Yes | Unclear | Yes | Yes | Unclear; No; No; No | Unclear; Unclear | Yes | Fair | NR |
| Sawitzke, 2008214 Sawitzke, 2010215 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes; No; Yes; No | No; No | Yes | Good | NIH |
| Scheiman, 2006261 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes, No, No, No | Yes, No | Yes | Fair | AstraZeneca |
| Silverstein, 200054 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | No; No; No; No | No; No | No | Good | Pharmacia |
| Simon, 2009301 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes; No; No; No | No; No | Yes | Good | Nuvo Research Inc |
| Temple, 2006183 | Yes | No | Yes | Yes | No | Yes | Yes | Yes; No; Yes; No | Yes; Yes | Yes | Fair | McNeil Consumer & Specialty Pharmaceuticals |
| Tiso, 2010302 | Yes | Yes | Yes | Yes | No | No | No | Yes; No; No; No | No; No | Yes | Fair | Helm Pharmaceuticals |
| Tugwell, 2004303 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes; No; Yes; No | No; No | Yes | Good | Dimethaid Healthcare Ltd. |
| Underwood, 200749 | Yes | Yes | Yes | Yes | No | No | No | Yes; Yes; Yes; Yes | No; Yes | No | Fair | NHS Health Technology Programme |
| Valat, 200167 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | Yes | Fair | NR |
| Wilkens, 2010208 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes; No; Yes; No | No; No | Yes | Good | Norwegian Foundation for Health and Rehabilitation |
| Wojtulewski, 199668 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | No; No; No; No | No; No | Yes | Fair | NR |
Quality ratings for the original 2006 CER available at: Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative Effectiveness Review No.6 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.). Rockville, MD: Agency for Healthcare Research and Quality, 2006. AHRQ Publication No. 06-EHC009.
From: Appendix G, Quality Assessment of Trials, Systematic Reviews, and Observational Studies*
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.